secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-04-22T23:59:59+00:00
Accession:  0000950170-24-046481
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista appoints William Fairey to Board; commercial expertise in rare disease
-------------------------------------------------------------------------------

- William Fairey appointed to Board effective April 18, 2024 as Class III director.
- Mr. Fairey previously served as Chief Commercial Officer at MyoKardia and COO at ChemoCentryx.
- Initial compensation includes options to purchase 17,000 shares and $42,500 annual cash retainer.
- Appointment adds commercial launch experience ahead of planned FDA submission for sebetralstat.
- Mr. Fairey is independent under Nasdaq and SEC rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/0000950170-24-046481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/kalv-20240418.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-046481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer